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Abstract Monogenic diabetes results from one or more
mutations in a single gene which might hence be rare but
has great impact leading to diabetes at a very young age. It
has resulted in great challenges for researchers elucidating
the aetiology of diabetes and related features in other organ
systems, for clinicians specifying a diagnosis that leads to
improved genetic counselling, predicting of clinical course
and changes in treatment, and for patients to altered
treatment that has lead to coming off insulin and injections
with no alternative (Glucokinase mutations), insulin injec-
tions being replaced by tablets (e.g. low dose in HNFα or
high dose in potassium channel defects -Kir6.2 and SUR1)
or with tablets in addition to insulin (e.g. metformin in
insulin resistant syndromes). Genetic testing requires
guidance to test for what gene especially given limited
resources. Monogenic diabetes should be considered in any
diabetic patient who has features inconsistent with their
current diagnosis (unspecified neonatal diabetes, type 1 or
type 2 diabetes) and clinical features of a specific subtype
of monogenic diabetes (neonatal diabetes, familial diabetes,
mild hyperglycaemia, syndromes). Guidance is given by
clinical and physiological features in patient and family and
the likelihood of the proposed mutation altering clinical
care. In this article, I aimed to provide insight in the genes
and mutations involved in insulin synthesis, secretion, and
resistance, and to provide guidance for genetic testing by
showing the clinical and physiological features and tests for
each specified diagnosis as well as the opportunities for
treatment.
Keywords Monogenicdiabetes.Neonataldiabetes.
Kir6.2.MODY.GCK.Insulinresistancesyndrome
1 Introduction
Monogenic diabetes is diabetes that results from one or
more mutations in a single gene. The mutation might have
arisen de novo and hence be a spontaneous case or might be
dominantly or recessively inherited. Molecular genetic
testing specifies a diagnosis in 1–2% [1]. The mechanism
can be easily understood from the underlying pathophysi-
ology. In children, almost all monogenic diabetes results
from mutations in genes that regulate β-cell function and
infrequently from mutations resulting in very severe insulin
resistance [2]. This article discusses the pathophysiology
and clinical manifestations used to select patients eligible to
genetic testing, and demonstrates the importance in the
treatment of monogenic diabetes.
2 Why diagnose monogenic diabetes?
Many patients with genetically proven monogenic diabe-
tes were initially incorrectly diagnosed. They received a
diagnosis of neonatal diabetes or diabetes diagnosed
before the age of 6 months that was not further specified
[3] or diagnosed as type 1 or type 2 diabetes [3–5]. It is
important to correctly diagnose monogenic diabetes be-
cause not only does it help to elucidate the aetiology of the
patient’s diabetes and explain other associated clinical
features, it can also predict the clinical course of the patient
and guide the most appropriate treatment. For instance,
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Fig. 1 Pancreatic β-cell and the genes involved in monogenic diabe-
tes. Mutationsindifferentgenesresultindifferentphenotypes(Tables1,
2, 3, and 4). Also, different mutations in the same gene might lead to
different phenotypes as shown in the spectrum of phenotypes in for
instance Kir6.2.
The upper part shows the physiological situation from insulin
synthesis to packaging and from glucose sensing to insulin secretion.
From centre to right: Insulin synthesis and packaging: Insulin (Ins)i s
synthesized in the nucleus regulated by transcription factors and after
translation in the endoplasmatic reticulum (ER) and Golgi apparatus
(Golgi) stored in granules. From left to right down: Glucose sensing
and insulin secretion: Glucose enters the β-cell by passive diffusion
facilitated by the glucose-transporter-2 (GLUT2). It is phosphorylated
by the enzyme glucokinase (GCK) to glucose-6-phosphate (G6P) and
metabolised to ATP via glycolysis or even further via the Krebs cycle
in the mitochondria (Mito). ATP closes the KATP channel, preventing
K
+ efflux, depolarising the cell membrane. Depolarisation opens
voltage dependent calcium channels (VDCC) allowing calcium influx.
The rise in intracellular calcium (Ca
2+) helps the insulin granules to
fuse with the cell membrane resulting in insulin secretion.
The lower part shows the pathological situation due to mutations
in the genes involved in monogenic diabetes. The proteins encoded by
the genes involved are given in bold type followed by the clinical
presentation if mutated (in brackets and italics). From centre to right:
Insulin synthesis is mainly influenced by nuclear transcription factors
that may also be involved in pancreatic development and hence
mutations may result in pancreatic atrophy (PTF1α, HNF1β)o r
agenesis (IPF1) rather than reduced insulin synthesis per se as in
TNDM (ZAC) or MODY (HNF1α, HNF4α, NEUROD1). Mutations
in genes that are involved in packaging of the insulin into granules in
the ER and Golgi apparatus result in TNDM (HYMAI), β-cell
destruction and PNDM (EIF2AK3 in Wolcott Rallison Syndrome—
WCRS), diabetes at a mean age of six as part of the Diabetes Insipidus,
Diabetes Mellitus, Optic Atrophy and Deafness syndrome (DID-
MOAD) alternatively called Wolfram syndrome (WRS) (WSF1), or in
diabetes as part of the Thiamine Responsive Megaloblastic Anaemia
Syndrome (TRMAS) alternatively called Roger’s syndrome. Mutations
in T-lymphocytes may also lead to β-cell destruction and PNDM as
seen with mutations in FOXP3 as part of the Immunodysregulation,
Polyendocrinopathy, Enteropathy, X-linked (IPEX) syndrome. From
left to right down: Glucose sensing is reduced by mutations in
GLUT2- leading to TNDM as part of the Fanconi-Bickel Syndrome,
GCK- resulting in MODY2 and mitochondrial DNA-interfering with
oxidative phosphorylation. These latter three mutations reduce ATP
and increase ADP leading to a decreased ATP/Mg-adenosine
diphosphate (ADP) ratio that activates the KATP channel to remain
open. Activating mutations in the KATP channel itself (Kir6.2/SUR1)
reduce sensitivity to ATP and hence also favour the open state of the
channel. The subsequent efflux of potassium prevents depolarisation
of the cell-membrane and hence prevents insulin secretion
172 Rev Endocr Metab Disord (2006) 7:171–185patients might not need any treatment or might be able to
switch from insulin injections to tablets such as sulfonylurea
[6, 7]. Finally a diagnosis has implications for other family
members often correcting their diagnosis, prognosis and
treatmentaswellasallowingappropriategeneticcounselling.
3 Normal insulin release and normal insulin sensitivity
The β-cells form the core of the islets of Langerhans and
are responsible for the synthesis and secretion of insulin
and C-peptide (Fig. 1, upper part). Insulin’s main function,
stimulating glucose uptake in peripheral tissue, is regulated
by insulin binding to insulin receptors on the cell
membrane of peripheral cells such as muscle cells. This
binding initiates an intracellular signalling cascade that
leads to an increase in the glucose influx (Fig. 2).
4 Abnormal insulin release and abnormal
insulin sensitivity
Most monogenic diabetes in children results from mutations
in genes causing β-cell loss or β-cell dysfunction and
hence affect insulin synthesis, packaging, glucose sensing
or insulin secretion (Fig. 1, lower part) [3, 8]. Mutations of
pancreatic transcription factors may result in reduced
pancreatic growth, (sub)total pancreatic agenesis or reduced
insulin synthesis per se and may present as neonatal
diabetes (ND), maturity onset diabetes of the young
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Fig. 2 Peripheral cell (e.g. muscle cell) showing the impact of diverse
mutations that result in insulin resistance. In the physiological
situation, insulin binds to the insulin receptor resulting in phosphor-
ylation (P) of a tyrosine (Y) residue of the insulin receptor substrate-1
(IRS1). This phosphorylation activates phosphatidylinositol 3-kinase
(PI3K) resulting in glucose transporter 4 (GLUT4) being translocated
to the cell membrane which in turn leads to glucose influx. In the
pathological situation, mutations in the insulin receptor interfere with
insulin receptor synthesis, posttranslational processing and intracellu-
lar-transport of the receptor to the cell membrane or lead to reduced
binding of insulin, reduced activation or increased degradation of the
receptor. The result is no phosphorylation of Y and hence eventually
no glucose uptake. This situation occurs in Type A severe insulin
resistance, Rabson-Mendenhall and Leprechaunism. In the presence of
high levels of triglycerides (TG) and hence free fatty acids (FFA)a
serine (S) residue is phosphorylated preventing phosphorylation of Y
and hence eventual glucose uptake. This situation occurs in congenital
generalised lipoatrophy and familial partial lipodystrophy. In all these
pathological situations, higher levels of insulin are needed for glucose
uptake and hence lead to reduced insulin sensitivity and insulin
resistance
Rev Endocr Metab Disord (2006) 7:171–185 173(MODY), or diabetes as part of a syndrome (Fig. 1, lower
part centre). Other mutations that affect insulin synthesis
are not expressed in the pancreatic β cell but in the CD4+
CD25+ regulatory T lymphocytes, where overactivation
results in auto-immunity against β-cells typically causing
diabetes in the first 3 months of life. Mutations affecting
translation, cleavage and packaging of insulin may result in
reduced β-cell number or reduced number of granules and
lower concentrations of insulin in these granules (Fig. 1
lower part right).
Mutations that affect insulin secretion involve genes that
regulate glucose sensing and affect beta-cell function rather
than its development or destruction. They include functional
mutations in mitochondrial DNA (Fig. 1, lower part left).
All these mutations reduce sensitivity to glucose and its
metabolism favouring the open state of the potassium
channels prevent depolarisation and hence insulin secretion.
In children, monogenic diabetes infrequently occurs from
mutations resulting in very severe insulin resistance (Fig. 2)
[2]. They are mainly caused by mutations in the insulin
receptor gene, that affect its synthesis and posttransla-
tional processing, increase receptor degradation, reduce
binding of insulin or receptor activation [9]. These give
rise to type A severe insulin resistance, Rabson-Mendenhall
syndrome or Leprechaunism [2, 9–11]. Alternatively,
insulin resistance may be the result of hypertriglycer-
idaemia associated with congenital generalised lipoa-
trophy or familial partial lipodystrophia [12, 13].
5 When to consider a diagnosis of monogenic diabetes?
Given the limited resources available it is vital that genetic
tests are used in situations where they are likely to be
positive and will alter clinical care. This will involve
careful clinical selection and physiological tests like C
peptide and autoantibody measurement as well as exami-
nation of other family members before doing molecular
genetic tests. Monogenic diabetes should be considered in
any diabetic patient who has features inconsistent with their
current diagnosis and clinical features of specific subtypes
of monogenic diabetes.
5.1 No specified diagnosis or features inconsistent
with current diagnosis
A diagnosis of diabetes might have been made without
further specifying the cause as in neonatal diabetes or
diabetes diagnosed below the age of 6 months. Also, the
majority of patients with genetically proven monogenic
diabetes are initially incorrectly diagnosed as Type 1 or
Type 2 diabetes [5].
5.1.1 No specified diagnosis of neonatal diabetes
or of diabetes diagnosed below the age of 6 months
Neonatal diabetes was defined as insulin requiring
diabetes diagnosed within the first 3 months of life. It is
an area that has rapidly transitioned from a clinical to a
molecular genetic classification [3, 14]. There is good
evidence that diabetes diagnosed in the first 6 months of
life is not type 1 diabetes because neither autoantibodies
typical for diabetes nor an excess of high type 1 HLA
susceptibility are found in these patients [15]. Diabetes
diagnosed before the age of 6 months irrespective of current
age should always lead to further molecular genetic testing.
Also because many years after diagnosis, patient and doctor
will find difficulty in recalling the exact age of diagnosis
and only be aware that it was ‘at very young age’. Features
that help differentiate between the different subtypes and
hence guide genetic testing are further described in the
section below and in Table 1.
5.1.2 Clinical features that are unusual for type 1 diabetes
Type 1 diabetes shares clinical features with certain types of
monogenic diabetes, such as young age of diagnosis,
normal body weight and insulinopaenia [5]s ot h a ta
monogenic diagnosis can be overlooked. Features in
children initially thought to have type 1 diabetes but that
should suggest a possible diagnosis of monogenic diabetes
are shown below. None of these are absolute and should be
considered collectively rather than in isolation [4]. The
approximate percentage of patients with type 1 diabetes is
given in brackets.
(1) Age of diagnosis below 6 months after birth (<1%) [15]
(2) Family history with a parent affected (2–4%) [16]
(3) Endogenous insulin production after 3 years of
diabetes (the honeymoon phase), indicated by
detectable C-peptide (>200 nmol/l) in response to
raised glucose (>8 mmol/l) (1–5%).
(4) Absence of islet autoantibodies, especially when mea-
sured at diagnosis (3–30%) [17, 18]. The great variation
in antibody prevalence in series probably represents
differences in assays and means it is hard to apply
published series directly into clinical practice. Absent
antibodies should lead to other investigation/consider-
ation rather than leading directly to genetic tests.
5.1.3 Clinical features that are unusual for type 2 diabetes
Type 2 diabetes in children and young adolescents might
share features which meet former classification criteria for
MODY such as diagnosed <25 years, autosomal dominant
inheritance and non-insulin dependency [19–22]. Patients
174 Rev Endocr Metab Disord (2006) 7:171–185might have a rather low body mass index and have other
features that are unusual for type 2 diabetes. These should
raise suspicion for the current diagnosis to be correct as
chances for these features occurring in type 2 diabetic
children or adolescents are low as shown here (percentage
shown in brackets).
(1) No evidence of insulin resistance with fasting C-peptide
within the normal range (0–20%) [19–22].
(2) Ethnicbackgroundfromalowprevalencetype2diabetes
race e.g. European Caucasian (0–45%) [19–22]
(3) Acanthosis nigricans not detected (10%) [19]
(4) Not markedly obese or diabetic family members who
are normal weight (20%) [22].
5.2 Clinical features of specific subtypes of monogenic
diabetes and their treatment
Typical clinical presentations in children when a diagnosis
of monogenic diabetes should be considered can mainly be
classified into four categories that are further discussed
below:
(1) Neonatal diabetes and diabetes diagnosed within the
first 6 months of life (Table 1)
(2) Familial diabetes with an affected parent (autosomal
dominant) (Table 2 upperpart)
(3) Mild (5.5–8.5 mmol/l) fasting hyperglycaemia espe-
cially if young or familial (Table 2 lower part).
(4) Features in other tissues as part of genetic syndromes
associated with diabetes (Tables 3 and 4)
5.2.1 Neonatal diabetes and diabetes diagnosed
before the age of 6 months irrespective of current age
Diabetes diagnosed before the age of 6 months is most
likely to have a genetic cause, and further clinical aspects
should be investigated to guide genetic testing. Clinically
two subgroups were recognised: transient neonatal diabetes
mellitus (TNDM) that resolved at a median of 12 weeks
and then did not require any treatment although as many as
50% of cases relapsed during the paediatric age range [23,
24]. In contrast permanent neonatal diabetes mellitus
(PNDM) required lifelong insulin injections from diagnosis
onwards. The majority of patients with TNDM have an
imprinting abnormality of the transcription factor ZAC gene
and HYMAI gene encoding an untranslated RNA chromo-
some 6q (Table1)[ 14, 23]. Apart from macroglossia seen in
23% there are no non-pancreatic features [23]. The second
commonest cause of mutations in patients with diabetes
diagnosed before the age of 6 months of life are mutations in
the KCNJ11 gene encoding the Kir6.2 subunit of the KATP
channel and that can result in either TNDM (10%) or
PNDM (90%) [3, 25–27]. Despite being a heterozygous
mutation most have no family history because 90% of cases
are spontaneous mutations. Most patients have isolated
diabetes although neurological features are seen in 20% of
patients. The most severe is the Developmental delay early
onset generalised Epilepsy and Neonatal Diabetes (DEND)
syndrome [25]. More common is the intermediate DEND
syndrome where patients have less severe developmental
delay and do not have early onset generalised epilepsy and
that is often associated with the V59M mutation [3, 26].
Recently, activating mutations in the ABCC8 gene encoding
the SUR1 subunit of the KATP channel were found to be a
similar cause of neonatal diabetes [28]. While the majority
of cases in PNDM are the result of mutations in the KCNJ11
gene, in a small minority of patients, many different genetic
mutations have been described [3]. If both parents are
glucose intolerant, homozygous or compound heterozygous
mutations in glucokinase are most frequent [29, 30].
Features that help differentiate between TNDM, PNDM
and the different subtypes, guide which gene to test for and
are described in Table 1.
Concerning treatment, imprinting abnormalities of the
6q24 locus show initially very high glucose values (range
12–57 mmol/l) and so insulin is used initially although the
dose can rapidly be reduced. Once patients have relapsed
patientsshouldremain under annual follow up due to the risk
of diabetes relapsing. Relapse patients are not insulin
dependent and can be treated with diet initially although
subsequently often need insulin [14]. The long-term
response to oral treatment such as sulfonylurea or metfor-
min is uncertain.
Patients with Kir6.2 mutations have all the clinical
features of insulin dependency as 30% present with
ketoacidosis and they usually do not have detectable C
peptide and so were treated with insulin [26]. It has recently
been shown that these patients cannot only be successfully
treated with oral sulfonylureas but can also get better
glycaemic control without an increase in hypoglycaemia
and with neurological features improving as well [70]. The
doses needed are high when calculated on a per kg body
weight basis compared to adults, with patients typically
needing 0.5 mg glibenclamide/kg/day although some may
need as much as 1 mg/kg/day [31–36, 70]. With time many
patients have been able to reduce their doses of sulfonyl-
urea while maintaining excellent glycaemic control [7, 70].
Similar results have recently been found for patients with
activating SUR1 mutations [37]. All other causes need to be
treated with insulin. Some paediatricians find these patients
are best managed on subcutaneous insulin pumps due to the
fluctuations in glucose levels. In patients with pancreatic
aplasia exocrine pancreatic supplements will additionally be
required.
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5.2.2.1 Children and young adults with a strong family
history of diabetes Genetic causes of a family history of
diabetes are autosomal dominant and non-insulin
dependent. A diagnosis of Maturity Onset Diabetes of the
Young (MODY) should be considered whenever a parent
has diabetes even if they are thought to have type 1 or type
2 diabetes (Table 2). MODY comes in two major
subgroups: (1) the result of transcription factor mutations
(IPF1-MODY4, HNF1β-MODY5, HNF1α-MODY3,
HNF4α-MODY1, NeuroD1-MODY6 or CEL-MODY7)
described in this section and (2) mutations reducing
glucose sensing (glucokinase mutations-MODY2) in
which a family history might be less evident because it
only presents as mild hyperglycaemia as described in the
following section. MODY due to transcription factor
mutations often present in adolescence/young adulthood,
show progressive hyperglycaemia and frequently lead to
complications. Of the transcription factor mutations,
MODY3—due to HNF1α mutations—is the commonest
form [38]. The clinical characteristics of patients with
HNF1α mutations are:
(1) Young onset diabetes that shows characteristics of not-
being insulin dependent e.g., do not develop keto-
acidosis in the absence of insulin, achieve good
glycaemic control on a small dose of insulin. Detect-
able C-peptide is measured when on insulin with
glucose >8 mmol/l after 3 years of diabetes (the
honeymoon period).
(2) Family history of diabetes. This might be insulin
treated and considered to be type 1 diabetes. This
would typically be diagnosed at their 20s, 30s or 40s.
There may also be an affected grandparent although
often these are diagnosed after 45 years.
(3) Glucosuria at relatively normal blood glucose levels
are often seen as these patients have a low renal
threshold [39].
(4) Oral glucose tolerance tests in early stages tend to show
a very large glucose increment usually >5 mmol/l [39].
Some patients might have a normal fasting value while
still rise into the diabetic range at 2 h.
(5) Marked sensitivity to sulfonylurea resulting in hypo-
glycaemia despite poor glycaemic control before
starting sulfonylurea [40,41].
Patients with HNF1α gene mutations can initially be
treated through diet although they will have marked
postprandial hyperglycaemia after high carbohydrate food
as the β-cell defect results in insufficient increase in insulin
secretion with hyperglycaemia [42]. Most patients will need
pharmacological treatment as they show progressive dete-
rioration in glycaemic control throughout life and are at risk
of considerable micro-vascular and macro-vascular compli-
cations [43]. The first treatment to be used in children who
are not controlled on insulin should be low dose sulfony-
lureas which results in a 4-fold greater lowering of glucose
than metformin [41]. These patients are extremely sensitive
to sulfonylurea and as long as they do not have problems
with hypoglycaemia can be maintained on these for many
decades [40]. Glycaemic control in sulfonylureas is often
better than that achieved on insulin especially in children
and young adults [44]. The dose of sulfonylureas should
initially be low (1/4 of the normal starting dose in adults) to
avoid hypoglycaemia. If there is hypoglycaemia despite
dose titration of a once or twice daily sulfonylurea
preparation such as Gliclazide, a slow release preparation
or mealtime doses with short-acting agents like nateglini-
dine may be considered [45].
Mutations in the hepatocyte nuclear factor 4α (HNF4α)-
gene resulting in MODY1 are considerably less common,
have similar characteristics but might be diagnosed later
and patients have no low renal threshold [46]. They also
lead to reduced levels of triglycerides and the apolipopro-
teins apoAIII and apoCIII [47]. Diagnosis should be
considered when HNF1α tests negative while the clinical
features are strongly suggestive for HNF1α [46]. Patients
with HNF4 α mutations are usually sensitive to sulfonyl-
urea [48].
The handful of families with autosomal dominant non-
insulin dependent diabetes that have further been described
include mutations in IPF1 (MODY4) [49], NeuroD1
(MODY6) [50,51], and recently the carboxyl ester lipase
(CEL) gene (MODY7) [52], but these are so unusual they
do not need to be tested for in children with diabetes except
in a research setting or when there are additional pheno-
types such as pancreatic exocrine dysfunction [52]. IPF has
been described under neonatal diabetes, NeuroD1 encodes a
transcription factor that binds to a critical Ebox motif on the
insulin promoter and plays a role in both pancreatic and
neuron development.
5.2.3 Mild (5.5–8.5 mmol/l) fasting hyperglycaemia
especially if young or familial
Raised fasting blood glucose in the range of 5.5 to
8.5 mmol/l is unusual in children and young adults. This
always raises concern that they may be about to develop
type 1 diabetes or have type 2 diabetes. However a
considerable proportion of these patients with persistent
mild fasting hyperglycaemia will have a heterozygous
mutation in the glucokinase gene. The phenotype associ-
ated with glucokinase mutations is remarkably similar for
178 Rev Endocr Metab Disord (2006) 7:171–185all mutations with the following features suggesting a
diagnosis.
(1) The fasting hyperglycaemia is persistent and stable
over a period of months or years [39]
(2) HbA1C is typically just below or just above the upper
limit of normal (5.5 to 5.7%)
(3) In an oral glucose tolerance test the increment
(2 h glucose-fasting glucose) is small (typically
<3.5 mmol/l) although because of the variability of
the oral glucose tolerance test this should not be
considered an absolute criteria [39].
(4) Parents may have ‘type 2 diabetes’ or may not be
diabetic. On testing one parent will have a mildly
raised fasting blood glucose, in the range of 5.5–
8.5 mmol/l, as this is an autosomal dominant condition
[39]. Testing of fasting glucose in apparently unaffect-
ed parents is important when considering a diagnosis
of a glucokinase mutation.
The fasting hyperglycaemia does not deteriorate signif-
icantly and the glucose is regulated at the higher set point
[39]. As this is rarely associated with any microvascular
or macrovascular complications even when no treatment
is given throughout life and as there is very little if any
response to either oral hypoglycaemic agents or insulin
because the set point remains the same, these patients do
not need treating in the paediatric age range [53].
5.2.4 Genetic syndromes associated with diabetes
When diabetes in a child is associated with other multi-
system disease the possibility of a monogenic syndrome
that explains all features should be considered. The online
Mendelian inheritance in Man (OMIM) website (access
through the NCBI website http://www.ncbi.nlm.nih.gov/
entrez/query.fcgi) can help with clinical features and to
know if the gene has been defined and hence molecular
genetic testing is available. For described and previously
undescribed syndromes see the ISPAD rare diabetes
collection (contact through link on the ISPAD website or
through http://www.diabetesgenes.org). The most common
genetic syndromes that include diabetes are described below
and in Tables 3 (insulin synthesis/secretion) and 4 (insulin
resistance).
5.2.4.1 MODY-5 due to an HNF-1β mutation (renal cysts
and diabetes syndrome The transcription factor hepatocyte
nuclear factor 1 β is expressed in primitive pancreatic duct
cells involved in early endocrine cell differentiation
incidentally leading to PNDM, but mainly leading to
MODY5 with pancreatic atrophy as a consistent finding
when assessed by abdominal computed tomography [54,
55]. Patients with HNF-1β mutations rarely present with
isolated diabetes [56]. Renal developmental disorders
especially renal cysts and renal dysplasia are present in
almost all patients with mutations or gene deletions [57].
These may be diagnosed in utero and precede the diagnosis
of diabetes. A diagnosis of HNF-1β should be considered
in any child with diabetes who also has non-diabetic renal
disease. Other features are presented in Table 3. Patients
with HNF1-β mutations, unlike patients with HNF-1α
mutations, are not sensitive to sulfonylurea and hence
usually require insulin treatment [58]. Pancreatic size is
reduced reflecting a reduction in both the endocrine and
exocrine pancreas and sub-clinical exocrine deficiency is
present in most patients [57] but it is uncertain if this should
be treated if it is asymptomatic.
5.2.4.2 Wolfram or DIDMOAD syndrome (diabetes
insipidus, diabetes mellitus, optic atrophy and deafness)
This autosomal recessive syndrome shows mutations in the
gene for Wolfram syndrome (WFS1) in at least 90% of
patients [59–61], and the association of diabetes with
progressive optic atrophy below 16 years of age is
diagnostic [62]. Other features are described in Table 3
with the complete phenotype seen in 75% of patients with
increasing prevalence with age. The order of appearance of
the neurological features may vary, even within families.
Patients with Wolfram syndrome die at a median age of
30 years [62]. The diabetes is non-autoimmune and insulin
deficient and presents at a mean age of 6 years [62].
Patients require insulin treatment from the time of diagnosis
but autoantibodies are not present [62].
5.2.4.3 Roger’s or TRMA syndrome (thiamine responsive
megaloblastic anaemia) The diabetes in this rare recessive
genetic syndrome, is insulin deficient in nature and both the
diabetes and the anaemia are responsive to thiamine.
However, all seem to develop an insulin requirement in
the long term [63]. Further details are described in Table 3.
5.2.4.4 Mitochondrial diabetes Maternal transmission of
mutated or deleted mitochondrial DNA (mtDNA) can result
in maternally inherited diabetes [64] although they do not
usuallyoccur in thepaediatric age range. Patientssufferfrom
sensorineural deafness and short stature. In family members
there might be some overlap between MIDD and MELAS
syndrome [65, 66]. The heteroplasmy in proportions of
mitochondrial DNA affected lead to a variety of phenotypes.
The diabetes is characterised by progressive non-
autoimmune β-cell failure, usually manifests outside the
paediatric age range, and may progress to needing insulin
treatment rapidly. Other features are described in Table 3.
5.2.4.5 Insulin resistance syndromes The key features of all
insulin resistance syndromes are acanthosis nigricans,
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182 Rev Endocr Metab Disord (2006) 7:171–185massively raised insulin concentrations, and androgen
excess while obesity is absent (Table 4)[ 2]. The more
severe the insulin resistance and the earlier the onset, the
more likely is diabetes. The mechanism of the main insulin
resistance syndromes, Type A, Rabson-Mendenhall,
Leprechaunism and Lipodystrophy, is shown in Fig. 2
while the key clinical features of the main insulin
syndromes, are presented in Table 4 [2]. Treatment of
severe insulin resistance is very difficult and most patients
with diabetes have poor glycaemic control and frequently
develop long-term complications [2]. Treatment approaches
include the use of the insulin sensitisers metformin and
glitazones, but effectiveness is limited when the insulin
resistance is very severe. Insulin is the main stay of
treatment and U500 insulin and insulin pumps are usually
required [2]. In partial lipodystrophy metformin may have
benefit and insulin is not required in the early stages [67].
In total lipodystrophy the response of diabetes to
recombinant lipodystrophy [68] can be dramatic but is
only available on a research basis.
6 Testing for a molecular monogenic diagnosis
6.1 How to test for monogenic diabetes?
While in type 1 and type 2 diabetes there is no single
diagnostic test, this is not the case in monogenic diabetes
where in >80% of cases a molecular genetic diagnosis can
be made by DNA testing. These are offered by many
laboratories but should preferably be performed in a
laboratory that is experienced and specialised in such diag-
nosis irrespective whether this requires sending samples
abroad (http://www.diabetesgenes.org). Some recently de-
scribed monogenicgenes, suchasKir6.2 inpatientsinwhom
diabetes was diagnosed before the age of 6 months, can be
screened for with no charge (http://www.diabetesgenes.org).
Other tests are more expensive (up to 500 Euro or 635
USD) but make future patient care cheaper and hence
testing would be cost-effective. For example, in a Swiss
centre yearly costs for type 1 diabetes was approximately
2050 Euro (2603 USD) per type 1 patient compared to 410
Euro (521 USD) per MODY2 patient [69]. Approval from
the patient’s insurance company should be sought prior to
sending DNA when applicable. Future analyses will show
cost-effectiveness for the different subtypes and prove
earlier diagnosis to be more beneficial.
6.2 What if a monogenic diagnosis cannot be made?
Occasionally molecular genetic test results are negative,
despite unusual clinical features or typical features for a cer-
tain monogenic subtype. The certainty of such a negative
result increases if a specialised centre performed testing.
Even then, some cases remain unsolved. These can be
referred to the ISPAD rare cases registry (see website or
contact a.t.hattersley@exeter.ac.uk) to allow pattern finding
and closer investigation by experts if a novel idea evolves,
hence increasing chances for new and future insights, novel
diagnoses and improved patient care.
7 Summary
Molecular genetic testing can define a diagnosis in 1–2%
of all diabetic patients with monogenic diabetes. Advances
in this field have led to the identification of the genes
associated with many clinically identified subgroups of
diabetes and explained clinical heterogeneity in conditions
defined by age of diagnosis e.g. neonatal diabetes and
MODY. Molecular genetic tests are now available to help
define the diagnosis, and importantly alter prognosis and
optimise treatment of children, young adults and their
families with diabetes. As these tests are expensive
genetic testing should be limited to those who on clinical
grounds are likely to be positive. Considering testing for
monogenic diabetes is hence a challenge and should be
guided by unusual features of the current diagnosis,
specific features concordant with monogenic subtypes
and by the possibility of a change in treatment. This
article discussed the pathophysiology and clinical mani-
festations used to select eligible patients and guide genetic
testing, and demonstrates its importance in the treatment
of monogenic diabetes.
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